Guilherme Nader Marta

@GuiNaderMarta

Medical Oncologist, Clinical Fellow @DanaFarber | @Harvard | Interested in breast cancer and cancer research

Boston, MA

Joined January 2020

944Following

1KFollowers

Guilherme Nader Marta@GuiNaderMarta · Jul 21

Honored to join the @myESMO Young Oncologists Committee! Grateful for the opportunity to contribute and help support the next generation of YOCs through education, mentorship, and global collaboration. Excited for what’s ahead!

GuiNaderMarta's tweet image. Honored to join the @myESMO Young Oncologists Committee!

Grateful for the opportunity to contribute and help support the next generation of YOCs through education, mentorship, and global collaboration.

Excited for what’s ahead!

2.0K

Guilherme Nader Marta Retweeted

Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc · Jul 18

Dr. Guilherme Nader Marta (@GuiNaderMarta) discussed #Immunotherapy in #TNBC, reviewing key questions after KEYNOTE-522: ❔Is the adjuvant phase truly necessary in pts with pCR? ❔Can we omit #anthracyclines from the chemo backbone? What is the ideal chemo partner? ❔What if…

3.0K

Guilherme Nader Marta Retweeted

Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc · Jul 18

Another excellent tumor board, this time focusing on advanced #BreastCancer, at the #HarvardBreastCancerCourse. Moderator: Dr. Rachel Freedman (@DrRFreedman) Panelists: Barbara Smith, Steven Isakoff, @elmayermd @PTarantinoMD, @VarellaLeticia1, @GuiNaderMarta, @daphskii

5.0K

Guilherme Nader Marta@GuiNaderMarta · Jul 18

Amazing discussion during the @Harvard Course tumor board on MBC. The rapidly increasing number of available treatment options complicates algorithms, raises opportunities for debate, and most importantly, improves patients’ outcomes. Exciting days for breast cancer treatment.

DDana-Farber’s Breast Oncology Center@DFCI_BreastOnc · Jul 18

5.0K

Guilherme Nader Marta Retweeted

Sara Tolaney@stolaney1 · Jul 17

Heather Jacene gives an outstanding talk on radiopharmaceuticals in breast cancer- a hot new field! @DFCI_BreastOnc #HarvardBreastCourse

823

Guilherme Nader Marta Retweeted

Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc · Jul 17

Starting Day 1 of the #HarvardBreastCancerCourse with welcoming remarks from Dr. Hal Burstein (@HaroldBurstein), who set the stage for a powerful day of insights, discovery, and collaboration. #BreastCancer @harvardmed

881

Guilherme Nader Marta Retweeted

Lobular Breast Cancer IRL #LivingWithLobular@LobularIreland · Jul 15

Thank you @GuiNaderMarta for sharing this newly published study Association of HER2-low with clinicopathological features in patients with early ILC Kudos to @VanBaelenKaren @ChristineDesme2 and all contributing authors and coauthors …ast-cancer-research.biomedcentral.com/articles/10.11…

702

Guilherme Nader Marta@GuiNaderMarta · Jul 15

New in @BCRJournal - Multicenter study led by @VanBaelenKaren of 2,098 pts w/ early ER+/HER2– lobular BC Over 50% had HER2-low tumors—associated with larger size, multifocality & worse DFS/OS vs HER2-0 Key insights for prognosis & treatment strategies @OncoAlert

GuiNaderMarta's tweet image. New in @BCRJournal - Multicenter study led by @VanBaelenKaren of 2,098 pts w/ early ER+/HER2– lobular BC

Over 50% had HER2-low tumors—associated with larger size, multifocality &amp; worse DFS/OS vs HER2-0

Key insights for prognosis &amp; treatment strategies

@OncoAlert

2.0K

Guilherme Nader Marta@GuiNaderMarta · Jul 15

Starts Thursday. Register for in person or virtual participation. Will be awesome .

DDana-Farber’s Breast Oncology Center@DFCI_BreastOnc · Jul 15

The #HarvardBreastCancerCourse starts on Thursday! 📅July 17 & 18 📍Westin Copley Place, Boston, MA The @harvardmed #BreastCancer course is well suited for medical, surgical & radiation oncologists; breast & general surgeons; internists; physician assistants; nurse practitioners,…

6.0K

Guilherme Nader Marta@GuiNaderMarta · Jul 10

Looking forward to two engaging days of learning and discussion at the #HarvardBreastCancerCourse — covering the latest in diagnosis, treatment, and survivorship! Join us in Boston or online, July 17–18! Register here 👇

DDana-Farber’s Breast Oncology Center@DFCI_BreastOnc · Jul 9

📢Reminder! The #HarvardBreastCancerCourse is next week on July 17 & 18! Check out our hashtag to see past speakers and topics. Register today to attend in person or virtually ⬇️⬇️ learn.hms.harvard.edu/programs/breas…

2.0K

Guilherme Nader Marta Retweeted

Elisabetta Bonzano MD, PhD@to_be_elizabeth · Jul 3

📌 Inavolisib-Based Triplet Therapy for PIK3CA-Mutated Hormone Receptor+/HER2- Breast Cancer: Clinical Implications and Practical Considerations 🔗 ascopubs.org/doi/pdf/10.120… @OncoAlert #OncoAlertAF @DFCI_BreastOnc @stolaney1 @elmayermd @GuiNaderMarta

2.0K

Guilherme Nader Marta@GuiNaderMarta · Jul 3

Inavolisib triplet approval marks real progress for pts w/ PIK3CA-mut HR+ mBC With progress come new questions—on pt selection, toxicity & integration into practice In this article we break down the data and its implications doi.org/10.1200/OA-25-… @DFCI_BreastOnc @OncoAlert

GuiNaderMarta's tweet image. Inavolisib triplet approval marks real progress for pts w/ PIK3CA-mut HR+ mBC

With progress come new questions—on pt selection, toxicity &amp; integration into practice

In this article we break down the data and its implications doi.org/10.1200/OA-25-…

@DFCI_BreastOnc
@OncoAlert

7.0K